Pharming Group N.V. (AMS:PHARM)

Netherlands · Delayed Price · Currency is EUR

1.393

+0.010 (0.72%)

At close: Feb 27, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Jan '20 Jan 1, 2020	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Ruconest®	252.24M	227.13M	205.62M	-	-
Ruconest® Growth	11.05%	10.46%	-	-	-
Joenja®	44.96M	18.18M	-	-	-
Joenja® Growth	147.28%	-	-	-	-
Recombinant Human C1 Esterase Inhibitor Business	-	-	-	198.87M	212.17M
Recombinant Human C1 Esterase Inhibitor Business Growth	-	-	-	-6.27%	12.03%
Total	297.20M	245.32M	205.62M	198.87M	212.17M
Total Growth	21.15%	19.30%	3.39%	-6.27%	12.03%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Jan '20 Jan 1, 2020	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States (US)	287.15M	239.11M	200.08M	193.42M	202.68M
United States (US) Growth	20.09%	19.50%	3.44%	-4.57%	11.19%
Europe and The Rest of The World	10.05M	6.21M	5.54M	5.45M	-
Europe and The Rest of The World Growth	61.88%	12.08%	1.61%	-	-
Europe	-	-	-	-	8.23M
Europe Growth	-	-	-	-	45.75%
Rest of World	-	-	-	-	1.26M
Rest of World Growth	-	-	-	-	-13.06%
Total	297.20M	245.32M	205.62M	198.87M	212.17M
Total Growth	21.15%	19.30%	3.39%	-6.27%	12.03%

Source: S&P Global Market Intelligence.